Horizon Therapeutics Plc (HZNP)

27.27
NASDAQ : Health Technology
Prev Close 26.50
Day Low/High 26.46 / 27.44
52 Wk Low/High 16.56 / 29.44
Avg Volume 1.80M
Exchange NASDAQ
Shares Outstanding 186.45M
Market Cap 4.94B
EPS -0.50
P/E Ratio 68.38
Div & Yield N.A. (N.A)
Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees.

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA).

Horizon Pharma Plc Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Horizon Pharma Plc Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 14,081,632 of its ordinary shares at a price to the public of $24.

Horizon Pharma Plc Announces Pricing Of Public Offering Of Ordinary Shares

Horizon Pharma Plc Announces Pricing Of Public Offering Of Ordinary Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 12,244,898 of its ordinary shares at a price to the public of $24.

Horizon Pharma Plc Announces Proposed Public Offering Of Ordinary Shares

Horizon Pharma Plc Announces Proposed Public Offering Of Ordinary Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced that it is offering to sell $300,000,000 of its ordinary shares in an underwritten public offering.

Celebrating the Greatness of Individual Traders

Celebrating the Greatness of Individual Traders

Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on March 1, 2018 of inducement restricted stock units for an aggregate of 8,544 ordinary shares to six new employees.

Noteworthy Thursday Option Activity: HZNP, WSM, HABT

Noteworthy Thursday Option Activity: HZNP, WSM, HABT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Horizon Pharma plc , where a total of 17,761 contracts have traded so far, representing approximately 1.8 million underlying shares. That amounts to about 104.2% of HZNP's average daily trading volume over the past month of 1.7 million shares.

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease.

Horizon Pharma Plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) For The Treatment Of Active Thyroid Eye Disease (TED) Met Primary And All Secondary Endpoints

Horizon Pharma Plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) For The Treatment Of Active Thyroid Eye Disease (TED) Met Primary And All Secondary Endpoints

Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).

Horizon Pharma Plc Reports Record Fourth-Quarter And Full-Year 2018 Net Sales Driven By Orphan And Rheumatology Segment; Announces Full-Year 2019 Guidance

Horizon Pharma Plc Reports Record Fourth-Quarter And Full-Year 2018 Net Sales Driven By Orphan And Rheumatology Segment; Announces Full-Year 2019 Guidance

Horizon Pharma plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2018 financial results and provided its full-year 2019 net sales and adjusted EBITDA guidance.

Horizon Pharma Plc To Participate In Cowen And Company 39th Annual Health Care Conference

Horizon Pharma Plc To Participate In Cowen And Company 39th Annual Health Care Conference

Horizon Pharma plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in March: Cowen and Company 39 th Annual Health Care Conference Date: March 11, 2019 Presentation Time: 12 p.

PepsiCo, Ford Motor, Teladoc: 'Mad Money' Lightning Round

PepsiCo, Ford Motor, Teladoc: 'Mad Money' Lightning Round

Jim Cramer weighs in on PepsiCo, Ford Motor, Teladoc, First Majestic Silver, Horizon Pharmaceuticals, Campbell Soup.

The Value of Patience: Cramer's 'Mad Money' Recap (Wednesday 1/30/19)

The Value of Patience: Cramer's 'Mad Money' Recap (Wednesday 1/30/19)

The Fed opted to exercise patience and see what happens with the economy -- and both the American people and the financial markets benefit.

Horizon Pharma Plc To Release Fourth-Quarter And Full-Year 2018 Financial Results And Host Webcast On Feb. 27, 2019

Horizon Pharma Plc To Release Fourth-Quarter And Full-Year 2018 Financial Results And Host Webcast On Feb. 27, 2019

Horizon Pharma plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2018 financial results will be released on Wednesday, Feb.

Horizon Pharma Plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout

Horizon Pharma Plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout

Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout.

Horizon Pharma Plc To Present At The 37th Annual J.P. Morgan Healthcare Conference

Horizon Pharma Plc To Present At The 37th Annual J.P. Morgan Healthcare Conference

Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the 37 th Annual J.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FL, HZNP Downgrades: EQT, FCB, GV, HSTM, KEYS, LMB, METC, OII, SAH, TCBI, WAB Initiations: REDU Read on to get TheStreet Quant Ratings' detailed report:

Horizon Pharma Plc To Participate In Upcoming Conferences

Horizon Pharma Plc To Participate In Upcoming Conferences

Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences: 30 th Annual Piper Jaffray Healthcare Conference Date: Nov.

Horizon Pharma Plc Reports Third-Quarter Net Sales Growth Of 20 Percent Driven By Orphan And Rheumatology Net Sales Growth Of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance

Horizon Pharma Plc Reports Third-Quarter Net Sales Growth Of 20 Percent Driven By Orphan And Rheumatology Net Sales Growth Of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance

Horizon Pharma plc (NASDAQ: HZNP) today announced its third-quarter 2018 financial results, confirmed its full-year 2018 net sales guidance range and increased its adjusted EBITDA guidance range.

The Chicago Tribune Names Horizon Pharma Plc A 2018 Top Workplace

The Chicago Tribune Names Horizon Pharma Plc A 2018 Top Workplace

Horizon Pharma plc (Nasdaq: HZNP) has been awarded a 2018 Top Workplaces honor by the Chicago Tribune.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BXMT, CHK, CHMI, CWEN, CWEN.A, EBMT, EFC, HASI, HIIQ, HMST, HTBI, HY, HZNP, JTPY, KNDI, LARK, LMRK, MBI, MFNC, MFSF, PBFX, RC, TEUM, UBNK, URG Downgrades: APTV, CFBK, CNFR, CPLP, CVEO, HF, HNGR, HPJ, IAG, INS, LGL, MAA, MCRN, MDRX, MHH, MTLS, NFBK, NUVA, OFED, OMI, VTSI, WNC, WSTL Initiations: I, ONS Read on to get TheStreet Quant Ratings' detailed report:

Horizon Pharma Plc Announces Presentation Of Results Of 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab At 2018 American Academy Of Ophthalmology (AAO) Annual Meeting

Horizon Pharma Plc Announces Presentation Of Results Of 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab At 2018 American Academy Of Ophthalmology (AAO) Annual Meeting

Horizon Pharma plc (NASDAQ:HZNP) announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the...

Horizon Pharma Plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates Of Gout And Increased Disease Severity

Horizon Pharma Plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates Of Gout And Increased Disease Severity

Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in...

Horizon Pharma Plc To Participate In Investor Conferences In November

Horizon Pharma Plc To Participate In Investor Conferences In November

Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences in November: Stifel 2018 Healthcare Conference Date: Wednesday, Nov.

Horizon Pharma Plc Announces Multiple Data Presentations Highlighting The Growing Burden Of Uncontrolled Gout At The 2018 ACR/ARHP Annual Meeting

Horizon Pharma Plc Announces Multiple Data Presentations Highlighting The Growing Burden Of Uncontrolled Gout At The 2018 ACR/ARHP Annual Meeting

Horizon Pharma plc (Nasdaq: HZNP) today announced that multiple studies demonstrating the extensive burden of uncontrolled gout and its impact on patients will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health...

FORTUNE And Great Place To Work® Name Horizon Pharma Plc To 2018 Best Small & Medium Workplaces For Third Consecutive Year

FORTUNE And Great Place To Work® Name Horizon Pharma Plc To 2018 Best Small & Medium Workplaces For Third Consecutive Year

Horizon Pharma plc (Nasdaq: HZNP) today announced that it has been named one of the 2018 Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the third consecutive year.

Horizon Pharma Plc To Release Third-Quarter 2018 Financial Results and Host Webcast On Nov. 7, 2018

Horizon Pharma Plc To Release Third-Quarter 2018 Financial Results and Host Webcast On Nov. 7, 2018

Horizon Pharma plc (Nasdaq: HZNP) announced today that its third-quarter financial results will be released on Wednesday, Nov.

Horizon Pharma Plc Announces Presentation Of Data From 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab

Horizon Pharma Plc Announces Presentation Of Data From 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab

Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24...

TheStreet Quant Rating: C+ (Hold)